Use of Bioprinted 3D Human Tissues for the Assessment of Drug Toxicity
Presented live on June 2016
Presenter: Sharon Presnell, Ph.D., Chief Scientific Officer, Organovo
Moderator: Deb Nguyen, Ph.D., Senior Director of R&D, Tissue Applications, Organovo
Human tissue biology is strongly influenced by the unique interplay and extensive cross talk that exists between different resident cell populations. These cell types are most often spatially arranged in a specific architecture which defines their biological function and mechanistic response to drug treatment over time. Three-dimensional bioprinted tissues that model this cellular complexity and form offer major advantages over conventional in vitro systems with respect to predictive modeling. Our tissues incorporate key architectural features and primary cell types and can be maintained in culture on a timescale of several days to weeks. We can apply our technology to design various tissues, including liver, kidney, skin, and oncology models. Here, we present specific case studies using exVive3D™ Human Liver Tissue to assess drug toxicity via various modalities including acute to chronic dosing, metabolite-driven toxicity, and fibrosis induced liver injury.
Dr. Sharon Presnell holds a Ph.D. in pathology from the Medical College of Virginia. As the Chief Scientific Officer at Organovo, Dr. Presnell has led the growth and development of the R&D organization, including evolution of the company’s technology portfolio.